Do the drug doses of conventional synthetic DMARDs used for the treatment of biologic/targeted-synthetic DMARDs naive rheumatoid arthritis patients affect QuantiFERON-TB Gold Plus test results?-Reference-Cited by-同舟云学术

Do the drug doses of conventional synthetic DMARDs used for the treatment of biologic/targeted-synthetic DMARDs naive rheumatoid arthritis patients affect QuantiFERON-TB Gold Plus test results?

Published:2023-04-01 Issue:8 Volume:43 Page:1445-1451
ISSN:1437-160X
Container-title:Rheumatology International
language:en
Short-container-title:Rheumatol Int

Author:

Ozsoy Zehra^ORCID,Ozdemir Adem,Ekici Mustafa,Bilgin Emre,Kılıc Levent,Kiraz Sedat,Sarıbas Zeynep,Sener Burçin,Karadag Omer

Publisher

Springer Science and Business Media LLC

Subject

Immunology,Immunology and Allergy,Rheumatology

Link

https://link.springer.com/content/pdf/10.1007/s00296-023-05320-7.pdf

Reference23 articles.

1. Dinser R, Fousse M, Sester U, Albrecht K, Singh M, Kohler H, Muller-Ladner U, Sester M (2008) Evaluation of latent tuberculosis infection in patients with inflammatory arthropathies before treatment with TNF-alpha blocking drugs using a novel flow-cytometric interferon-gamma release assay. Rheumatology (Oxford) 47(2):212–218. https://doi.org/10.1093/rheumatology/kem351

2. Lee H, Park HY, Jeon K, Jeong BH, Hwang JW, Lee J, Cha HS, Koh EM, Kang ES, Koh WJ (2015) QuantiFERON-TB Gold In-Tube assay for screening arthritis patients for latent tuberculosis infection before starting anti-tumor necrosis factor treatment. PLoS ONE 10(3):e0119260. https://doi.org/10.1371/journal.pone.0119260

3. Seyhoglu E, Uyaroglu OA, Erden A, Kilic L, Karadag O, Akdogan A, Bilgen SA, Ertenli I, Kiraz S, Kalyoncu U (2021) QuantiFERON(R)-TB Gold In-Tube test can be used for screening latent tuberculosis before biological treatment in a Bacille Calmette-Guerin (BCG)-vaccinated country: the HUR-BIO single-center real-life results. Clin Rheumatol 40(5):2027–2035. https://doi.org/10.1007/s10067-020-05443-3

4. Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V, Montero D, Pascual-Gomez E, Mola EM, Carreno L, Figueroa M, Group B (2005) Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 52(6):1766–1772. https://doi.org/10.1002/art.21043

5. Fragoulis GE, Nikiphorou E, Dey M et al (2022) EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases [published online ahead of print, 2022 Nov 3]. Ann Rheum Dis. https://doi.org/10.1136/ard-2022-223335